PROFENID 50mg caps.

Ülke: Mısır

Dil: İngilizce

Kaynak: EDA (Egyptian Drug Authority)

Mevcut itibaren:

SANOFI AVENTIS-FRANCE

Doz:

50 mg

Farmasötik formu:

capsule

Paketteki üniteler:

24 capsules

Tarafından üretildi:

ALEXANDRIA

Yetkilendirme tarihi:

1995-08-01

Bilgilendirme broşürü

20/07/2011 16:28 - VISTAlink folder 730160 - Page 1/4
S3 CARDIOVASCULAR RISK
NSAIDs may cause an increased risk of serious cardiovascular
thrombotic events, myocardial infarction, and stroke, which
can be fatal. This risk may increase with duration of use. Patients
with cardiovascular disease or risk factors for cardiovascular disease
may be at greater risk • NSAIDs is contraindicated for the treatment
of peri-operative pain in the setting of coronary artery bypass graft
(CABG) surgery. GASTROINTESTINAL RISK
NSAIDs cause an increased risk of serious gastrointestinal adverse
events including inflammation, bleeding, ulceration, and perforation
of the stomach or intestines, which can be fatal. These events can
occur at any time during use and without warning symptoms.
Elderly patients are at greater risk for serious gastrointestinal
events.
COMPOSITION
Each capsule contains
_Active ingredient:_ Ketoprofen ………..50mg
_Inactive ingredient:_ Lactose & magnesium stearate.
PHARMACEUTICAL FORM
Capsules.
PHARMACOLOGICAL ACTION
Pharmacodynamics:_ _Ketoprofen is a non-steroidal, anti-inflammatory
arylcarboxylic acid derivative belonging to the propionic acid group
of
NSAIDs. Ketoprofen has anti-inflammatory, antipyretic properties and
has
central and peripheral analgesic activity. However, its mode of action
is
not fully explained. It inhibits prostaglandin synthetase and platelet
aggregation.
_Pharmacokinetics:_
Absorption: Ketoprofen is rapidly and completely absorbed from the
gastrointestinal tract. Maximal plasma levels are reached within 60 to
90
minutes after oral administration (45 to 60 minutes after rectal
administration). When ketoprofen is administered with food, the rate
of
absorption is slowed, resulting in delayed and reduce peak
concentration
(Cmax); however, its total bioavailibility is not altered.
*Sustained-released formulations: when administered with high caloric
food, a slight decrease of bioavailibility (13%) has been observed.
For the
different slow-release formulations available in the differe